StreetInsider.com News Articles

Engene Holdings (ENGN) Reiterated at Market Perform by Citizens

Wed, 09 Sep 2026 04:17:16 -0400

Citizens analyst Silvan Turkcan reiterated a Market Perform rating on Engene Holdings Inc. (NASDAQ: ENGN).

The analyst commented, "enGene Holdings reported a 3Q26 update ahead of a key regulatory update and landmark CR rates from LEGEND in 4Q26, after which the company plans to file an IND. We met with ENGN management last week to discuss its view on the non-muscle invasive bladder cancer (NMIBC) market. We maintain our Market Perform rating with shares currently trading (~$122M market cap) at a 54% discount to cash reserves of $266M; therefore, we view shares as fairly valued, consistent with biotech peers facing similar

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932832.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932832.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932220.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932220.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925050.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925050.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26918741.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26918741.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26913527.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26913527.html

Form 8-K enGene Therapeutics Inc. For: Aug 11

Tue, 11 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26905492.html

Form 8-K enGene Therapeutics Inc. For: Aug 11

Tue, 11 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26905492.html

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

Tue, 04 Aug 2026 08:00:00 -0400

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations driving treatment selection.